GMJ Therapeutics specializes in advanced analytical technologies aimed at enhancing the efficiency of biotherapeutic development and omics research, particularly in proteomics and metabolomics. Their proprietary OptoESI™ interface integrates optical detection methods with mass spectrometry (MS), allowing for sensitive analysis of proteins and other biomolecules. This technology is complemented by their CeMAX UV™ system, which utilizes next-generation capillary electrophoresis to facilitate rapid and reliable charge-based analyses. These innovations are designed to streamline workflows in biopharmaceutical characterization, enabling researchers to achieve comprehensive results in significantly reduced timeframes.

The company’s technologies also cater to specific applications in the life sciences, such as vaccine development and gene therapy, by providing ultra-sensitive optical detection capabilities. Their solutions minimize sample waste through innovative designs, like the nanovial for small sample volumes. GMJ Therapeutics is committed to revolutionizing analytical workflows, thereby increasing productivity and efficiency for researchers at all stages of biopharmaceutical development. Their focus on integrating advanced detection methods with robust analytical tools positions them as a leader in the field of life sciences.

United States

GMJ Technologies, Inc. develops novel analytical technologies for efficient analytical workflows in biotherapeutic development and omics technologies

GMJ Therapeutics

Company Details